banner
LiverSource »  Faculty »  Hepatology »  Marion G. Peters, M.D.

Marion G. Peters, M.D.

Professor, Department of Medicine
John V. Carbone, M.D., Endowed Chair in Medicine
Chief of Hepatology Research

Contact Information

Appointments: (415) 353-2318
marion.peters@ucsf.edu
Open Popup
  • Melbourne University Medical School, Melbourne, Australia, M.B.B.S., 1972, Medicine
  • St. Vincent's Hospital Medical School, Melbourne, Australia, Medicine
  • Melbourne University, M.D., 1991, Medicine/Immunology
  • 1973-76 Resident and Registrar in Internal Medicine, St.Vincent's Hospital, Melbourne, Australia
  • 1976-77 Clinical Research Registrar to Dr. I. R. Mackay, Royal Melbourne Hospital and The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
  • 1977-78 Gastroenterology Registrar, St. Vincent's Hospital, Melbourne, Australia
  • 1978-80 Clinical Research Fellow in Hepatology to Dr. T. B. Reynolds, University of Southern California, Los Angeles, CA
  • 1980-83 Visiting Fogarty Fellow to Dr. A.S. Fauci, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD
  • 1983-85 Visiting Staff Fellow to Liver Diseases Section, National Institute of Arthritis,  Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD
  • American Board of Internal Medicine, Internal Medicine
  • UCSF Liver Center
  • Member, UCSF Immunology Graduate Program
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Liver Injury and Repair
  • Viral hepatitis and the role of the host immune response.

Dr. Marion Peters is a Professor of Medicine and holds the John V. Carbone, M.D., Endowed Chair in Medicine. She is also Chief of Hepatology Research. Dr. Peters is especially interested in the immunology of chronic liver diseases, particularly viral and autoimmune hepatitis. Her research activities include studies of transgenic mouse models of liver specific T cell responses, HIV and HCV coinfection, and alcohol and HCV infection.

Dr. Peters graduated from Melbourne University Medical School, Australia in 1972. She trained in gastroenterology, hepatology and immunology at St. Vincent's Hospital, Melbourne, University of Southern California and National Institutes of Health. She was Chief of Hepatology and medical director of Liver Transplantation at Washington University School of Medicine from 1985 to 1998.

My major interest is in viral hepatitis and the role of the host immune response. My work focuses on interactions among alcohol use, cannabis use and HIV co-infection on fibrotic outcomes of HCV infection. We are currently evaluating the  predictors of progression of liver disease in HIV and HCV coinfected women within the Women's Interagency HIV Study (WIHS): the role of alcohol, cannabis, HIV status and control as well as reproductive aging on the severity and rate of progression of liver disease.

We are also studying adherence to antiretroviral therapy in HIV/HCV co-infected women and on HCV-specific and innate immune responses in persons co-infected with HCV and HIV. I work within the AIDS Clinical Trial Group to develop clinical trials in viral hepatitis and HIV and within the Women's Interagency HIV Study (WIHS) to examine predictors of liver-related morbidity and mortality in a cohort of women with HIV/HCV infection.

 

  1. Luetkemeyer AF, Charlebois ED, Hare CB, Black D, Smith A, Havlir DV, Peters MG. Resistance Patterns and Response to Entecavir Intensification Among HIV-HBV-Coinfected Adults With Persistent HBV Viremia. J Acquir Immune Defic Syndr. 2011 Nov 1; 58(3):e96-9. 
  2. Kuniholm MH, Gao X, Xue X, Kovacs A, Marti D, Thio CL, Peters MG, Greenblatt RM, Goedert JJ, Cohen MH, Minkoff H, Gange SJ, Anastos K, Fazzari M, Young MA, Strickler HD, Carrington M. The Relation of HLA Genotype to Hepatitis C Viral Load and Markers of Liver Fibrosis in HIV-Infected and HIV-Uninfected Women. J Infect Dis. 2011 Jun; 203(12):1807-14. 
  3. Coffin CS, Mulrooney-Cousins PM, Peters MG, van Marle G, Roberts JP, Michalak TI, Terrault NA. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J Viral Hepat. 2011 Jun; 18(6):415-23. 
  4. Anthony DD, Umbleja T, Aberg JA, Kang M, Medvik K, Lederman MM, Peters MG, Koziel MJ, Overton ET. Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals. Vaccine. 2011 Apr 27; 29(19):3558-63. 
  5. Sherman KE, Andersen JW, Butt AA, Umbleja T, Alston B, Koziel MJ, Peters MG, Sulkowski M, Goodman ZD, Chung RT. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr. 2010 Dec 15; 55(5):597-605. 

 

X